Literature DB >> 22807253

Increase of body mass index in a tight controlled methotrexate-based strategy with prednisone in early rheumatoid arthritis: side effect of the prednisone or better control of disease activity?

Maud S Jurgens1, Johannes W G Jacobs, Rinie Geenen, Ercolie R Bossema, Marije F Bakker, Johannes W J Bijlsma, Iet A van Albada-Kuipers, Johan C Ehrlich, Floris P J G Lafeber, Paco M J Welsing.   

Abstract

OBJECTIVE: To clarify whether increase of body weight in patients with early rheumatoid arthritis (RA) upon administration of prednisone is a side effect of prednisone or a result of better control of disease activity, we examined the association of prednisone and disease activity with a subsequent change in body mass index (BMI).
METHODS: In the Computer Assisted Management in Early Rheumatoid Arthritis Trial-II, patients ages ≥18 years with early RA (disease duration <1 year and no prior use of disease-modifying antirheumatic drugs) had been randomized to a methotrexate (MTX)-based tight control strategy with either 10 mg of prednisone (MTX + prednisone) or placebo (MTX + placebo). The MTX + prednisone group had lower disease activity, but gained more weight than the MTX + placebo group (mean ± SD 2.9 ± 4.2 kg versus 1.3 ± 5.3 kg; P = 0.03). Data from patients with monthly measurements of disease activity (Disease Activity Score in 28 joints [DAS28]) and BMI were analyzed with a longitudinal regression (mixed model) analysis with BMI as the dependent variable and treatment strategy and DAS28 as the independent variables, correcting for baseline BMI and possible confounders (sex, age, and rheumatoid factor status).
RESULTS: There was no independent association of glucocorticoid therapy with a change in BMI, but a lower DAS28 was associated with an increased BMI 6 months later. The association of the DAS28 with BMI was most strongly present in postmenopausal women. Clinical cutoff points showed a clear association between DAS28 level and the change in BMI 6 months later.
CONCLUSION: Weight gain during treatment with prednisone seems attributable to a reduction of disease activity and is probably, at least partly, regained weight.
Copyright © 2013 by the American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22807253     DOI: 10.1002/acr.21797

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  9 in total

1.  Predictors of longterm changes in body mass index in rheumatoid arthritis.

Authors:  Joshua F Baker; Grant W Cannon; Said Ibrahim; Candace Haroldsen; Liron Caplan; Ted R Mikuls
Journal:  J Rheumatol       Date:  2015-04-01       Impact factor: 4.666

2.  A systematic review of the association of obesity with the outcomes of inflammatory rheumatic diseases.

Authors:  Yi Xuan Lee; Yu Heng Kwan; Ka Keat Lim; Chuen Seng Tan; Nai Lee Lui; Jie Kie Phang; Eng Hui Chew; Truls Ostbye; Julian Thumboo; Warren Fong
Journal:  Singapore Med J       Date:  2019-06       Impact factor: 1.858

3.  Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Eli M Miloslavsky; Matthew Cascino; Sebastian H Unizony; Na Lu; Gary S Hoffman; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul A Monach; Philip Seo; Robert Spiera; E William St Clair; Ulrich Specks; Paul Brunetta; Hyon K Choi; John H Stone
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-07       Impact factor: 4.794

Review 4.  The Obesity Epidemic and Consequences for Rheumatoid Arthritis Care.

Authors:  Michael D George; Joshua F Baker
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

5.  Changes in Body Mass Related to the Initiation of Disease-Modifying Therapies in Rheumatoid Arthritis.

Authors:  Joshua F Baker; Brian C Sauer; Grant W Cannon; Chia-Chen Teng; Kaleb Michaud; Said Ibrahim; Erik Jorgenson; Lisa Davis; Liron Caplan; Amy Cannella; Ted R Mikuls
Journal:  Arthritis Rheumatol       Date:  2016-08       Impact factor: 10.995

Review 6.  The value of glucocorticoid co-therapy in different rheumatic diseases--positive and adverse effects.

Authors:  Marlies C van der Goes; Johannes W Jacobs; Johannes W Bijlsma
Journal:  Arthritis Res Ther       Date:  2014-11-13       Impact factor: 5.156

7.  Prevalence of rheumatoid cachexia in rheumatoid arthritis: a systematic review and meta-analysis.

Authors:  Rafaela C E Santo; Kevin Z Fernandes; Priscila S Lora; Lidiane I Filippin; Ricardo M Xavier
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-08-21       Impact factor: 12.910

Review 8.  How Do Glucocorticoids Used in Rheumatic Disease Affect Body Weight? A Narrative Review of the Evidence.

Authors:  Catharine Morgan; Ruth E Costello; David W Ray; William G Dixon
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-04       Impact factor: 5.178

9.  The association of body mass index with disease activity and clinical response to combination therapy in patients with rheumatoid arthritis.

Authors:  Maryam Mirpourian; Mansour Salesi; Hadi Abdolahi; Ziba Farajzadegan; Hadi Karimzadeh
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.